Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Hisamitsu Pharmaceutical Co., Ltd. to Dissolve Subsidiary and Sub-subsidiary
Hisamitsu Pharmaceutical Co., Ltd. announced that it has decided to dissolve its Saga-based 50%-owned sub-subsidiary, which had been engaged in the manufacturing and sale of medical products, as well as its Sago-based 50%-owned, which had been engaged in the trading and management of real estates. The liquidation will start after June 2012. The sub-subsidiary and subsidiary are now dormant companies.
Latest Developments for Hisamitsu Pharmaceutical Co Inc
- R&I Withdraws Rating on HISAMITSU PHARMACEUTICAL CO INC
- HISAMITSU PHARMACEUTICAL CO INC Raises Mid-year Consolidated Outlook for FY 2013
- Hisamitsu Pharmaceutical Co., Ltd. to Establish Joint Venture with sanofi-aventis K.K.
- Hisamitsu Pharmaceutical Co., Ltd. Announces Result of Phase III Clinical Trial for HTU-520
Latest Key Developments in Pharmaceuticals
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Medicines Co Announces Positive Results For Solo II Trial Of Oritavancin In Treatment Of Acute Bacterial Skin And Skin Structure Infections
- OHKI CO LTD Announces Concern of Uncollectible or Delayed Receivables
- CKD Bio Announces Resignation of Co-CEO
- Share this
- Link this
- Digg this
Follow Reuters